EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review

Keiichi Yamanaka iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17031 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Keiichi Yamanaka. Beteiligte Einrichtung: Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Pyoderma Gangrenosum, Dermatitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are stubborn inflammatory skin diseases categorized as neutrophilic hypodermal dermatoses. These conditions exhibit connections with other autoinflammatory disorders driven by immune responses. Their pathogenesis is complex, rooted in significant imbalances in both innate and adaptive immune systems, particularly featuring elevated levels of tumor necrosis factor‐α (TNF‐α), interleukin (IL)‐1, IL‐8, IL‐17, and IL‐23. Studies involving skin tissue pathology and serology have indicated that targeting specific cytokines can bring therapeutic benefits. Indeed, many patients in clinical settings have responded positively to such interventions. Yet, given the diverse cytokines in play, focusing on a single one with antibody therapy might not always be effective. When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaPyoderma GangrenosumDermatitisHumansSkinCytokines

Stichwörter der Autor:innen

hidradenitis suppurativainflammatory skin diseasekeratinocyteneutrophilpyoderma gangrenosum

Substanzen

Cytokines

Autor:innen und Institutionen

  • Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan.

ORCID-Profile: Keiichi Yamanaka

Zitieren

APA

Yamanaka, K. (2024). New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17031

Vancouver

Yamanaka K. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17031

BibTeX
@article{Yamanaka2024,
  author = {Yamanaka, Keiichi},
  title = {New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17031}
}
Kostenlos starten →